San Francisco, CA, November 16, 2023 – George Eleftheriou, Co-Founder & CEO of Feel Therapeutics, the leading digital precision medicine company that brings objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health, will be a featured speaker at the upcoming Johnson & Johnson Innovation - JLABS Precision Medicine symposium in Utrecht, Netherlands, on November 16, 2023.
“Feel Therapeutics, a San Francisco-based company with additional offices in Europe, is at the forefront of digital precision medicine for mental health. With the mission to bring objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health.”
Eleftheriou will participate in the panel discussion "Digital Applications for Real-World Evidence Studies" at 16:00 CET. The discussion will explore the significant advancements in leveraging digital biomarkers and measurement to reshape the way we generate Real World Evidence. The panel will explore the utilization of applications, wearable devices, and other techniques for collecting health-related data both inside and outside clinical settings. This includes standardizing and validating methods to obtain structured data aligned with the FAIR principles to ensure alignment with Real-World Evidence standards.
Feel Therapeutics, a San Francisco-based company with additional offices in Europe, is at the forefront of digital precision medicine for mental health. With the mission to bring objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health. Furthermore, Feel has partnerships with four of the largest pharma and life science companies to generate evidence in clinical and real-world studies, as well as to improve adherence and patient outcomes alongside medications.
Feel Therapeutics has the mission to bring digital precision medicine to mental health and has been selected to be a member of Johnson & Johnson Innovation - JLABS. For this symposium, Eleftheriou will be participating in a fireside chat alongside Elena Fernandez-Kleinlein, Head of JLABS EMEA at Johnson & Johnson Innovation. This chat will delve into the nuances and intricacies of digital precision medicine applications for mental health in the context of Real-World Evidence studies.
For more information about the symposium, please visit https://precision.splashthat.com. To learn more about Feel Therapeutics' work, please visit https://www.feeltherapeutics.com
Feel Therapeutics is a Digital Precision Medicine company bringing objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health.
The company is backed by top-tier investors and partners with Pharmaceutical companies and CROs to generate evidence and bring precision Drug+ and DTx solutions to market as standalone or alongside medications.
Feel Therapeutics is headquartered in San Francisco, with additional offices in Europe.
